doi:10.1186/s12866-023-03068-5...
BioMed Central
Mycology
2023
11/8/2023
Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance.
Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Results This study found that NAC combined with CZA effectively inhibits the growth of CZA-resistant clinical Enterobacterales strains.
The CZA/NAC combination inhibits biofilm formation in vitro and decreases bacterial burden in a mouse thigh infection model.
The combination is biocompatible and primarily increases cell membrane permeability to cause bacterial death.
Conclusions These findings prove that the CZA/NAC combination has potential as a treatment for CZA-resistant Enterobacterales infections.
Huang, Zeyu,Han, Yijia,Zhang, Xiaotuan,Sun, Yao,Lin, Yuzhan,Feng, Luozhu,Zhou, Tieli,Wang, Zhongyong, 2023, Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo, BioMed Central